Phase II trial of interferon-beta for treatment of recurrent glioblastoma multiforme

Twelve patients were admitted to a Phase II study on the treatment of recurrent glioblastoma multiforme with interferon-beta (IFN-beta). All patients had previously undergone craniotomy and received a standard course of radiation therapy. Recurrence was inferred from enlargement of the lesion on com...

Full description

Saved in:
Bibliographic Details
Published inJournal of neurosurgery Vol. 64; no. 3; p. 408
Main Authors Duff, T A, Borden, E, Bay, J, Piepmeier, J, Sielaff, K
Format Journal Article
LanguageEnglish
Published United States 01.03.1986
Subjects
Adult
Drug Evaluation
Female
Glioblastoma - diagnostic imaging
Glioblastoma - drug therapy
Glioblastoma - physiopathology
Humans
Interferon Type I - adverse effects
Interferon Type I - therapeutic use
Male
Middle Aged
Neoplasm Recurrence, Local - drug therapy
Nervous System - physiopathology
Radiography
Online AccessGet more information

Cover

More Information
Summary:Twelve patients were admitted to a Phase II study on the treatment of recurrent glioblastoma multiforme with interferon-beta (IFN-beta). All patients had previously undergone craniotomy and received a standard course of radiation therapy. Recurrence was inferred from enlargement of the lesion on computerized tomography (CT) scanning and in each case was confirmed by CT-guided stereotaxic biopsy. Treatment consisted of combined intravenous (10 X 10(6) IU/day) and intratumoral (1 X 10(6) IU every other day) administration of IFN-beta over three 10-day cycles. This regimen was well tolerated, with toxicity requiring temporary dose modifications in five patients. As judged from data from historical cases, however, the patients admitted to this study demonstrated no clear improvement in mean survival time. The findings of this study also emphasize the importance of distinguishing between radiation necrosis and tumor recurrence.
ISSN:0022-3085
DOI:10.3171/jns.1986.64.3.0408